Skip to main content
TEYI PHARMACEUTICAL GROUP CO.,LTD logo

TEYI PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002728 ISIN · CNE100001WK6 LEI · 300300ZUIZCFPGQWOZ61 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,596 across all filing types
Latest filing 2021-04-22 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002728

About TEYI PHARMACEUTICAL GROUP CO.,LTD

https://www.tczy.com.cn

TEYI PHARMACEUTICAL GROUP CO.,LTD. specializes in the research, development, manufacturing, and distribution of pharmaceutical products. The company's portfolio primarily consists of Chinese patent medicines and chemical drug preparations. Its flagship product, Zhike Bao Tablets, is widely recognized for treating chronic bronchitis and cough-related ailments. Beyond respiratory health, the group produces a diverse range of medications covering cardiovascular diseases, gastrointestinal disorders, and anti-infective treatments. Teyi Pharmaceutical operates modern production facilities and maintains a robust distribution network to serve healthcare providers and pharmacies. The company emphasizes the integration of traditional medicinal knowledge with modern pharmaceutical technology to enhance product efficacy and safety.

Recent filings

Filing Released Lang Actions
股票交易异常波动公告
Regulatory Filings Classification · 95% confidence The document is a stock trading abnormal fluctuation announcement by 特一药业集团股份有限公司. It discusses the stock price movement over specific dates, clarifies the company's operational status, and addresses the absence of undisclosed material information affecting stock price. It also includes risk warnings and references to prior disclosures. The document is short (1599 characters) and serves as a regulatory disclosure about stock price volatility rather than a financial report or earnings release. It does not contain financial statements or detailed financial data. This type of announcement fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other categories.
2021-04-22 Chinese
关于全资子公司药品阿莫西林胶囊通过一致性评价的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the approval of a pharmaceutical product (Amoxicillin capsules) by a regulatory authority (National Medical Products Administration). It details the approval notice, product specifications, and the impact on the company. The document is short (1158 characters) and serves as a formal public announcement rather than a detailed financial or management report. It does not contain financial statements, management discussion, or regulatory certifications. It is not an earnings release, annual report, or any detailed report type. It is a regulatory announcement about product approval and its business impact, fitting best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2021-04-21 Chinese
内部控制鉴证报告
Regulatory Filings
2021-04-20 Chinese
独立董事对担保等事项的独立意见
Regulatory Filings Classification · 95% confidence The document is an independent directors' opinion on various matters related to the company's 2020 fiscal year, including related party transactions, external guarantees, profit distribution proposals, fundraising usage, internal control evaluation, credit facilities, accounting policy changes, and extension of non-public stock issuance resolutions. It references compliance with regulatory guidelines and company rules but does not contain full financial statements or detailed financial data. The document is a formal opinion letter from independent directors rather than a full annual report or audit report. It is also not a brief announcement or a certification letter but a detailed opinion on governance and compliance matters. Therefore, it fits best under Regulatory Filings (RNS) as it is a regulatory compliance document that does not constitute a full financial report or other specific filing types.
2021-04-20 Chinese
东莞证券关于特一药业2020年度募集资金存放与使用情况的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed verification opinion from Dongguan Securities regarding the 2020 annual fundraising funds deposit and usage situation of a company. It includes detailed financial figures about the raised funds, their usage, storage, management, and audit opinions from an accounting firm. The document references regulatory rules and compliance with stock exchange listing rules. It is a specialized audit and verification report on the use of raised funds, not a full annual report or earnings release. It is not a simple announcement or publication notice but contains substantive financial and compliance information related to fundraising usage. Therefore, it fits best under the category of Audit Report / Information (AR), which covers standalone audit reports and applied accounting principles related to specific financial matters, excluding full annual reports. FY 2020
2021-04-20 Chinese
关于延长公司2020年非公开发行股票股东大会决议有效期及授权董事会全权办理相关事宜有效期延期的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the extension of the validity period of a shareholder meeting resolution related to a non-public stock issuance and the authorization of the board to handle related matters. It references a previous shareholder meeting resolution and regulatory approval from the China Securities Regulatory Commission. The document is short (1575 characters) and primarily serves as a formal announcement of the extension of the resolution's validity period rather than containing detailed financial data or the actual report of the issuance. It does not contain financial statements or substantive financial analysis. Therefore, it is best classified as a Capital/Financing Update (CAP) since it relates to the company's financing activities and capital structure changes through non-public stock issuance.
2021-04-20 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.